

Special Issue

Chronic Lymphocytic Leukemia (CLL): From Benchside to Bedside

Message from the Guest Editor

This Special Issue of the *Lymphatics* journal aims to enable the rapid publication of contributions and discoveries concerning all aspects of chronic lymphocytic leukemia (CLL) research, ranging from basic research to clinical applications, with the focus on the translational research. In the past few decades, with the new understanding of pathogenesis and molecular biology of CLL, the prognosis tools and targeted therapies have been greatly developed. However, it is still far from sufficient to reach robust conclusions and guidelines for treatment. We are pleased to invite you to share with us your perspectives and research results of CLL in the Collection. Topics include, but are not limited to, the following: - Normal B-cells and CLL B-cells - Genetics and genomics of CLL - Microenvironment - Molecular biology, pathology and diagnostics - Therapeutics, chemotherapy and chemoimmunotherapy - Therapeutics, novel targeted therapies including cellular therapies - Resistance mechanisms - Curing CLL

Guest Editor

Prof. Dr. Varsha Gandhi

MD Anderson Cancer Center disabled, University of Texas, Houston, TX, USA

Deadline for manuscript submissions

31 January 2025



Lymphatics

an Open Access Journal
by MDPI



mdpi.com/si/213006

Lymphatics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
lymphatics@mdpi.com

[mdpi.com/journal/
lymphatics](https://mdpi.com/journal/lymphatics)





Lymphatics

an Open Access Journal
by MDPI



[mdpi.com/journal/
lymphatics](https://mdpi.com/journal/lymphatics)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Varsha Gandhi
MD Anderson Cancer Center disabled, University of Texas, Houston, TX,
USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

first decisions in 16 days; acceptance to publication in 5.8 days (median values for MDPI journals in the first half of 2024).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.